Medtronic completes enrollment in pulsed-field ablation trial - Mass Device

Medtronic’s Sphere-9 mapping and ablation catheter [Photo courtesy of Medtronic]

Medtronic today announced it completed enrollment and last attraction successful the Sphere Per-AF pivotal proceedings to survey Affera’s pulsed-field ablation catheter tech.

The proceedings is evaluating the information and effectiveness of the Sphere-9. The Sphere-9 is simply a pulsed tract (PF) and vigor frequence (RF) ablation and high-density mapping catheter. Along with the Affera cardiac mapping and navigation platform, it treats atrial fibrillation.

Affera designed the exertion to diagnose, representation and dainty bosom arrhythmias with ablation. It scars bosom insubstantial to interrupt errant signals utilizing some radiofrequency ablation and non-thermal pulsed-field ablation technology. Medtronic acquired the institution for $1 cardinal successful August.

Get the afloat communicative connected our sister site, Medical Tubing + Extrusion.